Egham, UK – 19 January, 2022 – Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products essential to patients across multiple therapeutic areas, announces the appointment of Jenni White to the newly created position of Vice President of Commercial.
“We are delighted to have Jenni join the team at this pivotal stage at Essential Pharma, as we expand our sales portfolio and our market presence in Europe and the rest of the world” comments Steen Vangsgaard, Chief Executive Officer of Essential Pharma. “Jenni’s expertise in distribution and commercialisation of products internationally will be key to achieving our goal of becoming a leading global supplier of products that remain clinically essential for patients. Jenni’s commercial know-how and clear strategic focus will play an important role in further building the company’s speciality product platform.”
Jenni joins Essential Pharma from Bausch & Lomb where she worked as Business Unit Director of Pharmaceuticals for the UK and Ireland. Jenni’s most recent role included the management of distribution and company relationships alongside commercial contract negotiation with a focus on strategic planning and establishing product market capability. During this time, Jenni led the launch of multiple new products for the prescription market.
With over 25 years of international commercial experience, Jenni has successfully led sales and marketing teams in the UK, Ireland, and the Nordic Regions. Her expertise, in delivering growth across international pharmaceutical markets, includes a number of executive roles in the prescription pharmaceuticals, medical devices and consumer healthcare space.
“I am thrilled to join the Essential Pharma team who recognise the value and importance of long-standing therapies that are vital to treat unmet patient needs for a variety of medical conditions” added Jenni White. “I look forward to working with the management team to further develop Essential Pharma’s market reach and drive commercial growth for the business. As the company looks to expand its product portfolio, we will be looking to capitalise on the multiple opportunities available to acquire and consolidate mature, well-established products that provide positive impact for patients.”
Jenni holds a BSc (Hons) in Applied Biology/ Microbiology from Glasgow Caledonian University and began her pharmaceutical career at Astra Pharmaceuticals. Jenni subsequently went on to work at Merck, Sharpe & Dohme.